Nurix Therapeutics (NRIX) Long-Term Investments (2019 - 2024)

Nurix Therapeutics (NRIX) has 6 years of Long-Term Investments data on file, last reported at $9.5 million in Q3 2024.

• On a quarterly basis, Long-Term Investments fell 4.15% year-over-year to $9.5 million in Q3 2024; TTM through Aug 2024 was $9.5 million, a 4.15% decrease from a year earlier, with the FY2023 full-year figure at $7.4 million, down 88.38% from the prior year.
• Long-Term Investments for Q3 2024 stood at $9.5 million, up from $9.4 million in the prior quarter.
• Over the last five years, Long-Term Investments for NRIX reached as high as $137.2 million in Q4 2021 and fell as low as $7.4 million in Q4 2023.
• Historically, Long-Term Investments has averaged $59.3 million across 5 years, with a median of $51.5 million in 2022.
• Across the five-year window, Long-Term Investments surged 17862.45% in 2020 and plunged 88.38% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $90.9 million in 2020, then surged by 50.94% to $137.2 million in 2021, then sank by 53.44% to $63.9 million in 2022, then plunged by 88.38% to $7.4 million in 2023, then gained by 27.64% to $9.5 million in 2024.
• Per Business Quant data, the three most recent Long-Term Investments figures were $9.5 million in Q3 2024, $9.4 million in Q2 2024, and $10.3 million in Q1 2024.